San Francisco, California, United States EcoR1 Capital appeared to be the VC, which was created in 2012. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the San Francisco.
We also calculated 2 valuable employees in our database.
The usual cause for the fund is to invest in rounds with 8-9 partakers. Despite the EcoR1 Capital, startups are often financed by ARCH Venture Partners, Third Rock Ventures, The Column Group. The meaningful sponsors for the fund in investment in the same round are Fidelity Management and Research Company, Cormorant Asset Management, Samsara BioCapital. In the next rounds fund is usually obtained by Polaris Partners, Fidelity Management and Research Company, Cormorant Asset Management.
Among the most popular portfolio startups of the fund, we may highlight Clementia Pharmaceuticals, Relay Therapeutics, Codiak Biosciences. Among the most popular fund investment industries, there are Genetics, Medical Device. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little.
The increased amount of exits for fund were in 2018. The fund is generally included in 2-6 deals every year. Speaking about the real fund results, this VC is 15 percentage points less often commits exit comparing to other organizations. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Deals in the range of 50 - 100 millions dollars are the general things for fund. This EcoR1 Capital works on 22 percentage points more the average amount of lead investments comparing to the other organizations.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Ajax Therapeutics | $95M | 13 May 2024 | Cambridge, Massachusetts, United States | ||
Attovia Therapeutics | $105M | 09 May 2024 | Fremont, California, United States | ||
Accent Therapeutics | $75M | 23 Jan 2024 | Lexington, Kentucky, United States | ||
Terremoto Biosciences | $175M | 02 Nov 2023 | San Francisco, California, United States | ||
ReCode Therapeutics | $50M | 19 Sep 2023 | Dallas, Texas, United States | ||
Actio Biosciences | $55M | 12 Sep 2023 | San Diego, California, United States | ||
Paratus Sciences | $100M | 27 Feb 2023 | New York, New York, United States | ||
Dewpoint Therapeutics | $150M | 03 Feb 2022 | Cambridge, Massachusetts, United States | ||
NiKang Therapeutics | $200M | 26 May 2021 | Wilmington, Delaware, United States |
– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.
– Ajax Therapeutics, Inc. announced the completion of a $40m financing.
– The round was led by EcoR1 Capital LLC with participation from additional new investor, Boxer Capital, as well as co-founding investors Inning One Ventures and Schrödinger, Inc.
– Existing research collaboration partners, Memorial Sloan Kettering Cancer Center (MSK) and NYU Langone Health, also participated in the financing.
– Concurrent with the financing, Scott Platshon, Partner of EcoR1 Capital, will join the Ajax Board of Directors.
– Proceeds from the financing will support the advancement of Ajax’ lead drug development programs targeting hematologic malignancies.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Ajax Therapeutics | $95M | 13 May 2024 | Cambridge, Massachusetts, United States | ||
Attovia Therapeutics | $105M | 09 May 2024 | Fremont, California, United States | ||
Accent Therapeutics | $75M | 23 Jan 2024 | Lexington, Kentucky, United States | ||
Terremoto Biosciences | $175M | 02 Nov 2023 | San Francisco, California, United States | ||
ReCode Therapeutics | $50M | 19 Sep 2023 | Dallas, Texas, United States | ||
Actio Biosciences | $55M | 12 Sep 2023 | San Diego, California, United States | ||
Paratus Sciences | $100M | 27 Feb 2023 | New York, New York, United States | ||
Dewpoint Therapeutics | $150M | 03 Feb 2022 | Cambridge, Massachusetts, United States | ||
NiKang Therapeutics | $200M | 26 May 2021 | Wilmington, Delaware, United States |
